Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.38
SPPI's Cash to Debt is ranked lower than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. SPPI: 1.38 )
Ranked among companies with meaningful Cash to Debt only.
SPPI' s Cash to Debt Range Over the Past 10 Years
Min: 0.73  Med: 9.24 Max: 17918
Current: 1.38
0.73
17918
Equity to Asset 0.51
SPPI's Equity to Asset is ranked lower than
70% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SPPI: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
SPPI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.60 Max: 0.94
Current: 0.51
0.2
0.94
F-Score: 3
Z-Score: 0.60
M-Score: -3.69
WACC vs ROIC
3.83%
-21.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -25.06
SPPI's Operating margin (%) is ranked higher than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. SPPI: -25.06 )
Ranked among companies with meaningful Operating margin (%) only.
SPPI' s Operating margin (%) Range Over the Past 10 Years
Min: -484.81  Med: -45.89 Max: 30.17
Current: -25.06
-484.81
30.17
Net-margin (%) -31.24
SPPI's Net-margin (%) is ranked higher than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. SPPI: -31.24 )
Ranked among companies with meaningful Net-margin (%) only.
SPPI' s Net-margin (%) Range Over the Past 10 Years
Min: -443.64  Med: -44.65 Max: 35.19
Current: -31.24
-443.64
35.19
ROE (%) -22.14
SPPI's ROE (%) is ranked higher than
56% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. SPPI: -22.14 )
Ranked among companies with meaningful ROE (%) only.
SPPI' s ROE (%) Range Over the Past 10 Years
Min: -72  Med: -23.84 Max: 39.19
Current: -22.14
-72
39.19
ROA (%) -11.13
SPPI's ROA (%) is ranked higher than
64% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. SPPI: -11.13 )
Ranked among companies with meaningful ROA (%) only.
SPPI' s ROA (%) Range Over the Past 10 Years
Min: -61.52  Med: -12.49 Max: 23.98
Current: -11.13
-61.52
23.98
ROC (Joel Greenblatt) (%) -3405.69
SPPI's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. SPPI: -3405.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPPI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5547.35  Med: -1954.97 Max: 3089.46
Current: -3405.69
-5547.35
3089.46
Revenue Growth (3Y)(%) -15.40
SPPI's Revenue Growth (3Y)(%) is ranked lower than
69% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SPPI: -15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPPI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -4.60 Max: 202.1
Current: -15.4
0
202.1
» SPPI's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SPPI Guru Trades in Q1 2015

Paul Tudor Jones 38,000 sh (New)
Jim Simons 1,391,217 sh (+460.97%)
» More
Q2 2015

SPPI Guru Trades in Q2 2015

Jim Simons 1,785,917 sh (+28.37%)
Paul Tudor Jones Sold Out
» More
Q3 2015

SPPI Guru Trades in Q3 2015

Paul Tudor Jones 30,458 sh (New)
Jim Simons 1,773,517 sh (-0.69%)
» More
Q4 2015

SPPI Guru Trades in Q4 2015

Jim Simons 2,591,319 sh (+46.11%)
Paul Tudor Jones 39,787 sh (+30.63%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.06
SPPI's P/B is ranked higher than
67% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. SPPI: 2.06 )
Ranked among companies with meaningful P/B only.
SPPI' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.06 Max: 5.24
Current: 2.06
0.64
5.24
P/S 2.59
SPPI's P/S is ranked higher than
81% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. SPPI: 2.59 )
Ranked among companies with meaningful P/S only.
SPPI' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 3.78 Max: 467.69
Current: 2.59
1.06
467.69
PFCF 26.46
SPPI's PFCF is ranked higher than
53% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. SPPI: 26.46 )
Ranked among companies with meaningful PFCF only.
SPPI' s PFCF Range Over the Past 10 Years
Min: 6.65  Med: 16.48 Max: 76.12
Current: 26.46
6.65
76.12
POCF 61.49
SPPI's POCF is ranked lower than
82% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. SPPI: 61.49 )
Ranked among companies with meaningful POCF only.
SPPI' s POCF Range Over the Past 10 Years
Min: 6.62  Med: 13.42 Max: 73.08
Current: 61.49
6.62
73.08
Current Ratio 2.51
SPPI's Current Ratio is ranked lower than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SPPI: 2.51 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.62 Max: 16.82
Current: 2.51
1.02
16.82
Quick Ratio 2.45
SPPI's Quick Ratio is ranked lower than
66% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. SPPI: 2.45 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.52 Max: 16.8
Current: 2.45
1.02
16.8
Days Inventory 101.03
SPPI's Days Inventory is ranked higher than
58% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. SPPI: 101.03 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 78.11  Med: 109.12 Max: 281.63
Current: 101.03
78.11
281.63
Days Sales Outstanding 68.22
SPPI's Days Sales Outstanding is ranked lower than
52% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. SPPI: 68.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 100.74 Max: 138.24
Current: 68.22
9.09
138.24
Days Payable 351.75
SPPI's Days Payable is ranked higher than
90% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. SPPI: 351.75 )
Ranked among companies with meaningful Days Payable only.
SPPI' s Days Payable Range Over the Past 10 Years
Min: 89.64  Med: 286.45 Max: 7902.06
Current: 351.75
89.64
7902.06

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.15
SPPI's Price/Projected FCF is ranked higher than
84% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. SPPI: 1.15 )
Ranked among companies with meaningful Price/Projected FCF only.
SPPI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.42 Max: 7.58
Current: 1.15
0.99
7.58
Price/Median PS Value 0.68
SPPI's Price/Median PS Value is ranked higher than
66% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. SPPI: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
SPPI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 1.98 Max: 457.5
Current: 0.68
0.3
457.5
Price/Graham Number 4.38
SPPI's Price/Graham Number is ranked lower than
99.99% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. SPPI: 4.38 )
Ranked among companies with meaningful Price/Graham Number only.
SPPI' s Price/Graham Number Range Over the Past 10 Years
Min: 1.68  Med: 1.89 Max: 2.09
Current: 4.38
1.68
2.09
Earnings Yield (Greenblatt) (%) -10.30
SPPI's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. SPPI: -10.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPPI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.3  Med: 11.60 Max: 2183.8
Current: -10.3
-10.3
2183.8

More Statistics

Revenue(Mil) $163
EPS $ -0.78
Beta0.37
Short Percentage of Float18.17%
52-Week Range $4.14 - 7.74
Shares Outstanding(Mil)68.16

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 89 83 91
EPS($) -1.69 -1.42 -0.34
EPS without NRI($) -1.69 -1.42 -0.34

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Spectrum Pharma reports 1Q loss May 05 2016
Spectrum Pharma reports 1Q loss May 05 2016
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update May 05 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
4:05 pm Spectrum Pharma beats by $0.13, beats on revs May 05 2016
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update May 05 2016
Q1 2016 Spectrum Pharmaceuticals Inc Earnings Release - After Market Close May 05 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016... May 03 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016... May 03 2016
Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast Apr 28 2016
Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast Apr 28 2016
This Biotech Is Up 300% In Two Months Apr 20 2016
Spectrum Pharma Jumps on FDA Orphan Designation Apr 20 2016
FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple... Apr 20 2016
[$$] Companies Wind Up in the 'Penalty Box' on Executive Pay Apr 20 2016
[$$] Companies Wind Up in the ‘Penalty Box’ on Executive Pay Apr 20 2016
Four Biotech Stocks To Consider As The Sector Breaks Out Apr 07 2016
Existing Chemotherapy Drugs for Lymphoma Apr 07 2016
Six Technologies That Will Change Healthcare Apr 07 2016
ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : March 28, 2016 Mar 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK